Hypera S.A. (HYPMY) Research

Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid. Beyond prescription drugs, Hypera S.A. also provides dermo-cosmetic solutions, notably through its Mantecorp Skincare line. Its consumer health segment features well-known brands including Apracur, Benegrip, Coristina d, Engov, Epocler, and Estomazil, among others. Furthermore, the company offers nutritional and vitamin supplements, with labels such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. Hypera S.A. is also a producer and distributor of a range of similar and generic medicines, including its Neo Química brand, as well as products identified by active ingredients like Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel. Initially known as Hypermarcas S.A., the company officially rebranded to Hypera S.A. in February 2018. Its corporate headquarters are located in São Paulo, Brazil.

Open Hypera S.A. (HYPMY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.